Requestioning the Role of Prolonged Maintenance Chemotherapy in AML: Randomized Trial by the German AML Cooperative Group Updated.

Reviewer: Mary Kara Bucci, MD
The Abramson Cancer Center of the University of Pennsylvania
Last Modified: December 10, 2001

Share article

Presenter: Thomas Buechner
Presenter's Affiliation: German AML Cooperative Group
Type of Session: Scientific

The German AML Cooperative Group (GAMLCG) has previously reported a survival advantage to 3 years of montly maintenance chemotherapy after standard dose thioguanine/araC/daunorubicin (TAD) vs. no further treatment. This was initially reported in 1985 (JCO 3:1583, 1985). Ten-year update of the previously reported GAMLCG trial of TAD+maintenance vs. TAD alone shows a continued benefit in the maintenance arm, 18% relapse-free survival (RFS) vs 6% in the TAD-alone arm. Based on these results, the GAMLCG performed new randomized trial of 3 years of maintenance chemotherapy vs. no further treatment following a new chemotherapy regimen.

Materials and Methods

  • 817 patients (pts) were randomized to one of two treatment arms. Arm 1: TAD + high-dose araC/mitox(HAM) followed by TAD consolidation and monthly, low dose TAD maintenance. Arm 2: TAD-HAM-TAD + one course of HAM with adjusted dose araC (S-HAM) and no maintenance chemotherapy.
  • Median pt age was 54 (range, 16-82), with 35% over age 60.
  • Patient characteristics were evenly balances between the two groups.


  • Response to induction was not different between the two arms; complete response of 69% vs. 70% and partial response of 19% vs 18%.
  • 64% of pts in the maintenance arm received the intended treatment (full doses) and 44% of pts in the no-maintenance arm received full-dose treatment.
  • 5-year relapse-free survival (RFS) is 31% in the patients treated according to the maintenance arm vs 24% in the patients treated according to the no-maintenance arm, p=.014.
  • Survival at 5 years from treatment start is 27% (no difference between the two arms); survival 5 years from complete remission is 37% (no difference between the two groups)

    Author's Conclusions

  • By analysis according to treatment received, 5-year RFS is significantly higher in the maintenance arm.
  • There is no difference in the survival of the two groups.
  • Overall survival includes patients treated with second-line chemotherapy; the difference in RFS implies a greater chance of cure from first-line treatment alone in the maintenance group.

    Clinical/Scientific Implications
    The GAMLCG considers the maintenance regimen superior to the no-maintenance arm because of increased chance of cure from the first-line treatment alone. Currently, a trial is underway comparing maintenance chemotherapy as standard therapy vs. autologous bone marrow transplant.

    Oncolink's ASH Coverage made possible by an unrestricted Educational Grant from Amgen.

    Addition of Gemtuzumab Ozogamicin Ups Survival in AML

    Apr 9, 2012 - For patients with untreated de novo acute myeloid leukemia, the addition of gemtuzumab ozogamicin to standard frontline chemotherapy improves event-free, overall, and relapse-free survival, without causing excessive toxicity, according to a phase 3 study published online April 5 in The Lancet.

  • I Wish You Knew

    How cancer patients have changed my life

    View More

    Blogs and Web Chats

    OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.

    OncoLink OncoPilot

    Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

    Learn More